Published in Cancer Weekly, April 4th, 2006
According to recent research from Canada, "Thirty-one patients with metastatic colorectal cancer were enrolled in this phase I/II trial of a triple combination of C, O, and T, all given on day 1 of a convenient 3-week schedule. Patients received 257 cycles (1-18) in 5 cohorts."
"Toxicity was manageable and haematological toxicity was mild to moderate," explained J.A. Maroun and colleagues, Ottawa Hospital. "Diarrhoea was the main dose-limiting toxicity; nausea and vomiting were common. Fatigue was frequent, moderate in severity and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.